Lactate Imaging as a Tumour Biomarker

Institute of Cancer Research, United Kingdom37 enrolled

Overview

This project is designed to investigate whether measurements of lactate in tumours, made using a magnetic resonance technique similar to MRI, is an effective non-invasive method to detect whether some new targeted drugs are having their desired effect. The study hypothesis is that by using magnetic resonance spectroscopy techniques, we will be able to observe changes in tumour lactate levels in vivo, in response to treatment.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Cancer

Interventions

Magnetic Resonance Imaging (MRI)DEVICE

Magnetic Resonance Spectroscopy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Cohort 1:lymphoma patients * minimum lesion size of 2cm * not pretreated but scheduled to be treated with CHOP (Cyclophosphamide, Hydroxydaunomycin,Oncovin and Prednisolone) Cohort 2:Colorectal patients * metastatic disease of at least 2cm * not pretreated Cohort 3:Phase 1 Drug Development * minimum lesion size at least 2cm Cohort 4: Brain * primary brain tumours receiving radiotherapy and temozolomide * cerebral lymphoma receiving standard chemotherapy Exclusion Criteria: * MRI incompatible metal implants * Claustrophobia * Inability to tolerate a 40 minute MRI scan

Locations (1)

The Institute of Cancer Research and Royal Marsden NHS Foundation Trust

Sutton, Surrey, United Kingdom

Outcomes

Primary Outcomes

Correlation between changes in MRS lactate measurements at two time points after treatment and clinical response

Time frame: 7 and 21 days post treatment

Secondary Outcomes

Reproducibility of MRS lactate measurement

Time frame: Two baseline measurements taken at day -7 to 0 pre-treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.